SEC Form 4 · accession 0001144204-15-066918
HUMANIGEN, INC · HGEN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Marek Biestek
Other
Period of report
Nov 18, 2015
Accepted (ET)
Nov 19, 2015 · 1:53 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001293310
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Nov 18, 2015 | P | 40,000 | $2.04 | A | 240,000 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. Marek Biestek purchased 40,000 shares in multiple transactions at prices ranging from $2.01 to $2.12, inclusive. The reporting person undertakes to provide to Kalobios Pharmaceuticals, Inc., any security holder of Kalobios Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4.
- F2The securities reported herein are owned directly by Marek Biestek, who is a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934. Marek Biestek individually owns less than 10%. There is no voting or ownership agreement amongst the group members and the other members of the group do not have a pecuniary interest in the shares reported herein. Correspondingly, Mr. Biestek does not have a pecuniary interest in the shares owned by the other members of the group.
Remarks
Marek Biestek is a member of a "group" for purposes of Section 13(d) of the Exchange Act of 1934, but individually owns less than 10%.